Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin M Ellingson

Showing results (261-270 of 286) with videos related to

Pageof 29
Sort By:
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
The Lancet. Oncology|March 1, 2023
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshopLalitha K Shankar, Heiko Schöder, Elad Sharon, et al.
The Lancet. Oncology|January 5, 2024
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO groupNathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
Neuro-Oncology|July 22, 2025
The Use of Minor Response, Volumetric Assessment and Growth Rate Kinetics as Endpoints in Grade 1-3 Glioma Clinical Trials: a RANO perspectiveMartin J van den Bent, Timothy F Cloughesy, Benjamin M Ellingson, et al.
JAMA Oncology|October 31, 2024
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical TrialJann N Sarkaria, Karla V Ballman, Sani H Kizilbash, et al.
Neuro-Oncology|June 24, 2024
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Martin J van den Bent, Pim J French, Daniel Brat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2023
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent GlioblastomaGilbert Youssef, Rifaquat Rahman, Camden Bay, et al.
Neuro-Oncology|June 10, 2020
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomasJerrold L Boxerman, Chad C Quarles, Leland S Hu, et al.
Pageof 29

Showing results (261-270 of 286) with videos related to

Sort By:
Pageof 29
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
The Lancet. Oncology|March 1, 2023
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshopLalitha K Shankar, Heiko Schöder, Elad Sharon, et al.
The Lancet. Oncology|January 5, 2024
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO groupNathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
Neuro-Oncology|July 22, 2025
The Use of Minor Response, Volumetric Assessment and Growth Rate Kinetics as Endpoints in Grade 1-3 Glioma Clinical Trials: a RANO perspectiveMartin J van den Bent, Timothy F Cloughesy, Benjamin M Ellingson, et al.
JAMA Oncology|October 31, 2024
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical TrialJann N Sarkaria, Karla V Ballman, Sani H Kizilbash, et al.
Neuro-Oncology|June 24, 2024
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Martin J van den Bent, Pim J French, Daniel Brat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2023
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent GlioblastomaGilbert Youssef, Rifaquat Rahman, Camden Bay, et al.
Neuro-Oncology|June 10, 2020
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomasJerrold L Boxerman, Chad C Quarles, Leland S Hu, et al.
Pageof 29